Benefits of probiotic use on COVID-19: A systematic review and meta-analysis

Benefits of probiotic use on COVID-19: A systematic review and meta-analysis

SARS-CoV-2 is the virus that causes the new global pandemic, which has already resulted in millions of deaths, affecting the world's health and economy. Probiotics have shown benefits in a variety of diseases, including respiratory infections, and may be beneficial in the adjunctive treatment o...

Full description

Saved in:
Bibliographic Details
Published in:Critical reviews in food science and nutrition Vol. 64; no. 10; pp. 2986 - 2998
Main Authors: Neris Almeida Viana, Suelen, do Reis Santos Pereira, Tamires, de Carvalho Alves, Janaína, Tianeze de Castro, Caroline, Santana C. da Silva, Lucas, Henrique Sousa Pinheiro, Lúcio, Nougalli Roselino, Mariana
Format: Journal Article
Language:English
Published: United States Taylor & Francis 2024
Taylor & Francis Ltd
Subjects:
Clinical trials
Coronavirus
coronavirus 2019
Cough
COVID-19
Diarrhea
Dietary supplements
Health services
Humans
Medical treatment
Meta-analysis
Pandemics
Patients
Probiotics
Probiotics - therapeutic use
respiratory infections
Respiratory tract infection
Risk assessment
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Signs and symptoms
Systematic review
Viral diseases
viral infection
Coronavirus
viral infection
coronavirus 2019
respiratory infections
probiotics
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:SARS-CoV-2 is the virus that causes the new global pandemic, which has already resulted in millions of deaths, affecting the world's health and economy. Probiotics have shown benefits in a variety of diseases, including respiratory infections, and may be beneficial in the adjunctive treatment of COVID-19. This study analyzed the effectiveness of probiotics as adjunctive treatment in reducing symptoms of patients with COVID-19, through a systematic review with meta-analysis. The EMBASE (Elsevier), Pubmed, Scopus, Web of Science and International Clinical Trials Registry Platform (ICTRP) were searched through March 16, 2022. The risk ratio (RR) with 95% confidence intervals (CIs) was estimated using a fixed-effect model. RoB 2 and ROBINS I were used to assess the risk of bias of the included studies. Nine studies were included (7 clinical trials and 2 cohorts), of which three clinical trials comprised the meta-analysis. Results showed that probiotics were associated with a significant 51% reduction in symptoms reported by COVID-19 patients (RR 0.49, 95% CI 0.40-0.61). There was a significant improvement in cough (RR 0.56, 95% CI 0.37-0.83), headaches (RR 0.17, 95% CI 0.05-0.65), and diarrhea (RR 0. 33, 95% CI 0.12-0.96) of patients on probiotic therapy. These findings suggest that probiotic supplementation is effective in improving symptoms of COVID-19.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ISSN:1040-8398
1549-7852
1549-7852
DOI:10.1080/10408398.2022.2128713